Mouhanned Eliliwi, MD
Pulmonary Disease · Phoenix, AZNPI 1417453895
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 67.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $3,565 and has fallen 92.1% since, to $283 in 2025.
Across 24 payments — averaging $211.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$693
- Lilly USA, LLC$249
- Bayer$224
- Pulmonx Corporation$176
- AbbVie$125
- plus $165 from 4 others
What the payments were for
- Travel & lodging$61112%
- Food & beverage$1,83537%
- Education$2,50051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,439 |
| AstraZeneca | 6 | $693 |
| Lilly USA, LLC | 2 | $249 |
| Bayer | 2 | $224 |
| Pulmonx Corporation | 1 | $176 |
| AbbVie | 1 | $125 |
| Pinnacle Biologics, Inc | 1 | $76 |
| Getinge USA Sales, LLC | 2 | $55 |
| Edwards Lifesciences | 1 | $22 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,332
- LOKELMA$341
- MOUNJARO$249
- CHARTIS CATHETER$176
- ZEPHYR DELIVERY CATHETER$176
- ZEPHYR ENDOBRONCHIAL VALVE$176
- PULMONX CHARTIS TABLET CONSOLE$176
- BRILINTA$125
- BREZTRI$125
- Kerendia$125
- AIRSUPRA$102
How this compares
$5,071 in reported general payments places this provider in the 60th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva HandihalerTiotropium Bromide | 23 | $11,942 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $8,278 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $5,663 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,016 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $670 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.